281 related articles for article (PubMed ID: 27372520)
1. USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
Malapelle U; Morra F; Ilardi G; Visconti R; Merolla F; Cerrato A; Napolitano V; Monaco R; Guggino G; Monaco G; Staibano S; Troncone G; Celetti A
Lung Cancer; 2017 May; 107():41-49. PubMed ID: 27372520
[TBL] [Abstract][Full Text] [Related]
2. CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
Morra F; Merolla F; Criscuolo D; Insabato L; Giannella R; Ilardi G; Cerrato A; Visconti R; Staibano S; Celetti A
J Exp Clin Cancer Res; 2019 Feb; 38(1):90. PubMed ID: 30786932
[TBL] [Abstract][Full Text] [Related]
3. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
Morra F; Merolla F; D'Abbiero D; Ilardi G; Campione S; Monaco R; Guggino G; Ambrosio F; Staibano S; Cerrato A; Visconti R; Celetti A
Lung Cancer; 2019 Sep; 135():56-65. PubMed ID: 31447003
[TBL] [Abstract][Full Text] [Related]
4. The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
Morra F; Merolla F; Napolitano V; Ilardi G; Miro C; Paladino S; Staibano S; Cerrato A; Celetti A
Oncotarget; 2017 May; 8(19):31815-31829. PubMed ID: 28415632
[TBL] [Abstract][Full Text] [Related]
5. FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.
Morra F; Luise C; Merolla F; Poser I; Visconti R; Ilardi G; Paladino S; Inuzuka H; Guggino G; Monaco R; Colecchia D; Monaco G; Cerrato A; Chiariello M; Denning K; Claudio PP; Staibano S; Celetti A
Oncotarget; 2015 May; 6(14):12697-709. PubMed ID: 25885523
[TBL] [Abstract][Full Text] [Related]
6. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
7. Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN.
Collaud S; Tischler V; Atanassoff A; Wiedl T; Komminoth P; Oehlschlegel C; Weder W; Soltermann A
BMC Cancer; 2015 Feb; 15():74. PubMed ID: 25884169
[TBL] [Abstract][Full Text] [Related]
8. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
9. The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status.
Wang M; Zhang Y; Wang T; Zhang J; Zhou Z; Sun Y; Wang S; Shi Y; Luan X; Zhang Y; Wang Y; Wang Y; Zou Z; Kang L; Liu H
Cell Physiol Biochem; 2017; 43(5):1755-1766. PubMed ID: 29049989
[TBL] [Abstract][Full Text] [Related]
10. USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth.
An T; Gong Y; Li X; Kong L; Ma P; Gong L; Zhu H; Yu C; Liu J; Zhou H; Mao B; Li Y
Biochem Pharmacol; 2017 May; 131():29-39. PubMed ID: 28216017
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic perspectives in CCDC6 deficient lung cancer cells.
Morra F; Luise C; Visconti R; Staibano S; Merolla F; Ilardi G; Guggino G; Paladino S; Sarnataro D; Franco R; Monaco R; Zitomarino F; Pacelli R; Monaco G; Rocco G; Cerrato A; Linardopoulos S; Muller MT; Celetti A
Int J Cancer; 2015 May; 136(9):2146-57. PubMed ID: 25302833
[TBL] [Abstract][Full Text] [Related]
12. USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis.
Peng Y; Liu Y; Gao Y; Yuan B; Qi X; Fu Y; Zhu Q; Cao T; Zhang S; Yin L; Li X
J Exp Clin Cancer Res; 2019 Nov; 38(1):468. PubMed ID: 31730000
[TBL] [Abstract][Full Text] [Related]
13. USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase.
Giovinazzi S; Morozov VM; Summers MK; Reinhold WC; Ishov AM
Cell Death Differ; 2013 May; 20(5):721-31. PubMed ID: 23348568
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors.
Chen C; Song J; Wang J; Xu C; Chen C; Gu W; Sun H; Wen X
Bioorg Med Chem Lett; 2017 Feb; 27(4):845-849. PubMed ID: 28108249
[TBL] [Abstract][Full Text] [Related]
15. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
[TBL] [Abstract][Full Text] [Related]
16. Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors.
Cheng X; Zhang B; Guo F; Wu H; Jin X
Mol Oncol; 2022 Apr; 16(7):1591-1607. PubMed ID: 34854226
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
Carrà G; Panuzzo C; Torti D; Parvis G; Crivellaro S; Familiari U; Volante M; Morena D; Lingua MF; Brancaccio M; Guerrasio A; Pandolfi PP; Saglio G; Taulli R; Morotti A
Oncotarget; 2017 May; 8(22):35508-35522. PubMed ID: 28418900
[TBL] [Abstract][Full Text] [Related]
18. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
[TBL] [Abstract][Full Text] [Related]
19. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Schauer NJ; Liu X; Magin RS; Doherty LM; Chan WC; Ficarro SB; Hu W; Roberts RM; Iacob RE; Stolte B; Giacomelli AO; Perera S; McKay K; Boswell SA; Weisberg EL; Ray A; Chauhan D; Dhe-Paganon S; Anderson KC; Griffin JD; Li J; Hahn WC; Sorger PK; Engen JR; Stegmaier K; Marto JA; Buhrlage SJ
Sci Rep; 2020 Mar; 10(1):5324. PubMed ID: 32210275
[TBL] [Abstract][Full Text] [Related]
20. CCDC6: the identity of a protein known to be partner in fusion.
Cerrato A; Merolla F; Morra F; Celetti A
Int J Cancer; 2018 Apr; 142(7):1300-1308. PubMed ID: 29044514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
